Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Capital Leases (2023 - 2025)

Bioharvest Sciences has reported Capital Leases over the past 3 years, most recently at $10.1 million for Q4 2025.

  • For Q4 2025, Capital Leases rose 10.82% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 10.82%, while the annual FY2025 figure was $10.1 million, 10.82% up from the prior year.
  • Capital Leases was $10.1 million for Q4 2025 at Bioharvest Sciences, up from $9.1 million in the prior quarter.
  • Across five years, Capital Leases topped out at $10.1 million in Q4 2025 and bottomed at $1.4 million in Q4 2023.
  • The 3-year median for Capital Leases is $9.1 million (2024), against an average of $6.9 million.
  • Year-over-year, Capital Leases skyrocketed 541.47% in 2024 and then increased 10.82% in 2025.
  • Over 3 years, Capital Leases stood at $1.4 million in 2023, then skyrocketed by 541.47% to $9.1 million in 2024, then increased by 10.82% to $10.1 million in 2025.
  • The last three reported values for Capital Leases were $10.1 million (Q4 2025), $9.1 million (Q4 2024), and $1.4 million (Q4 2023) per Business Quant data.